Skip to main content
ARS Home » Research » Publications at this Location » Publication #166968

Title: ARTEMISIA ANNUA AS A TRADITIONAL HERBAL ANTIMALARIAL

Author
item WILCOX, MERLIN - RITAM (OXFORD, UK)
item BODEKER, GERARD - UNIV OF OXFORD MED SCHOOL
item BOURDY, GENEVIEVE - CENTER IRD (FRANCE)
item DHINGRA, VIKAS - UNIVERSITY OF GEORGIA
item FALQUET, JACQUES - ANTENNA TECH (SWITZERLD)
item Ferreira, Jorge
item GRAZ, BERTRAND - IUMSP (SWITZERLAND)
item HIRT, HANS-MARTIN - ANAMED (GERMANY)
item HSU, ELISABETH - UNIVERSITY OF OXFORD (UK)
item DE MAGALHAES, PEDRO - CPQBA-UNICAMP (BRAZIL)
item PROVENDIER, DAMIEN - NOMAD RSI (FRANCE)
item WRIGHT, COLIN - UNIVERSITY OF BRADFORD

Submitted to: Book Chapter
Publication Type: Book / Chapter
Publication Acceptance Date: 2/1/2004
Publication Date: 6/1/2004
Citation: Wilcox, M., Bodeker, G., Bourdy, G., Dhingra, V., Falquet, J., Ferreira, J.F., Graz, B., Hirt, H., Hsu, E., De Magalhaes, P.M., Provendier, D., Wright, C. 2004. Artemisia annua as a traditional herbal antimalarial. In: Wilcox, M.L., Bodeker, G., Rasoanaivo, editors. Traditional Medicinal Plants and Malaria, Boca Raton, FL: CRC Press. 4: 43-59.

Interpretive Summary:

Technical Abstract: Artemisinin is the only natural antimalarial after quinine and is currently used in over 100 countries to fight chloroquine-resistant Plasmodium falciparum. Because artemisinin synthesis produces final yields lower than 4%, Artemisia annua is the only commercial source of the compound. Artemisia annua is also being considered for traditional antimalarial use as a tea. This work reviews the ethnopharmacology, clinical efficacy, evolution of resistance, safety, and tolerability of artemisinin and its related antimalarials as well as some points about the cultivation of A. annua and its public health potentials if used as a traditional herbal antimalarial. This review aims to explore the possibilities on the supervised and responsible cultivation and use of Artemisia annua as a traditional preparation (tea) by the poor people of Africa, who cannot afford current antimalarials produced by pharmaceutical companies.